1.Date of occurrence of the event:2022/08/16
2.Company name:Universal Vision Biotechnology Co., Ltd.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):The company itself.
4.Reciprocal shareholding ratios: N/A
5.Name of the reporting media:Economic Daily News
6.Content of the report: Entering peak season, Universal Vision Biotechnology
is looking to continue to grow in cataract and refractive treatments, on top
of increasing demands of OK lenses at back to school season. 3Q revenue is
estimated to reach 900 million, up by 40% hitting a new record high. 3Q EPS
is estimated to be $3 TWD.
7.Cause of occurrence:Mass media reporting
8.Countermeasures:The Company didn't provide financial forecasts.The
contents of reporting were speculations by the press and institutional
investors.Official announcements shall take precedence for actual financial
numbers.
9.Any other matters that need to be specified:None.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Universal Vision Biotechnology Co. Ltd. published this content on 16 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 August 2022 07:31:07 UTC.
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD is a Taiwan-based company principally engaged in the trading of ophthalmic supplies and the provision of eye treatment and related medical services. The Company provides laser vision correction equipment and services, as well as the trading of medical drugs, optical glasses and contact lenses. In addition, the Company is involved in the leasing of medical places, the planning of clinic operation, as well as the provision of medical cosmetology services. The Company operates its businesses mainly in Taiwan market.
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. 
